Phase III Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Peficitinib (Primary) ; Etanercept
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 10 Jun 2017 Biomarkers information updated
- 29 Nov 2016 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
- 29 Nov 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.